

10/694,843

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1201txs

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America  
NEWS 2 "Ask CAS" for self-help around the clock  
NEWS 3 SEP 01 New pricing for the Save Answers for SciFinder Wizard within  
STN Express with Discover!  
NEWS 4 OCT 28 KOREAPAT now available on STN  
NEWS 5 NOV 18 Current-awareness alerts, saved answer sets, and current  
search transcripts to be affected by CERAB, COMPUAB, ELCOM,  
and SOLIDSTATE reloads  
NEWS 6 NOV 30 PHAR reloaded with additional data  
NEWS 7 DEC 01 LISA now available on STN  
NEWS 8 DEC 09 12 databases to be removed from STN on December 31, 2004  
  
NEWS EXPRESS OCTOBER 29 CURRENT WINDOWS VERSION IS V7.01A, CURRENT  
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),  
AND CURRENT DISCOVER FILE IS DATED 11 AUGUST 2004  
NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS INTER General Internet Information  
NEWS LOGIN Welcome Banner and News Items  
NEWS PHONE Direct Dial and Telecommunication Network Access to STN  
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that  
specific topic.

All use of STN is subject to the provisions of the STN Customer  
agreement. Please note that this agreement limits use to scientific  
research. Use for software development or design or implementation  
of commercial gateways or other similar uses is prohibited and may  
result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 18:23:13 ON 09 DEC 2004

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 18:23:20 ON 09 DEC 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 American Chemical Society (ACS)

10/694,843

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 8 DEC 2004 HIGHEST RN 795251-52-4  
DICTIONARY FILE UPDATES: 8 DEC 2004 HIGHEST RN 795251-52-4

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004


Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:  
<http://www.cas.org/ONLINE/DBSS/registryss.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10694843.str



chain nodes :

17 18 19 20 21 22 23 25 26 27 28 33 34

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

chain bonds :

1-8 3-25 4-16 9-17 11-19 13-18 18-33 18-34 19-20 19-27 19-28 20-21  
20-26 21-22 21-23

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-11 8-9 9-10 10-11 12-13 12-16 13-14  
14-15 15-16

exact/norm bonds :

1-8 4-16 7-8 8-9 9-17 12-16 15-16 18-33 18-34 19-20 20-21 21-23

exact bonds :

3-25 7-11 9-10 10-11 11-19 12-13 13-14 13-18 14-15 19-27 19-28 20-26  
21-22

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6

isolated ring systems :

containing 1 : 7 : 12 :

G1:O,S

G2:O,OH,CN,N,X,Hy,Ak

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom  
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:CLASS 18:CLASS 19:CLASS  
20:CLASS 21:CLASS 22:CLASS 23:CLASS 25:CLASS 26:CLASS 27:CLASS 28:CLASS  
33:CLASS 34:CLASS

10/694,843

L1 STRUCTURE UPLOADED

=> s l1

SAMPLE SEARCH INITIATED 18:24:04 FILE 'REGISTRY'  
SAMPLE SCREEN SEARCH COMPLETED - 7 TO ITERATE

100.0% PROCESSED 7 ITERATIONS 4 ANSWERS  
SEARCH TIME: 00.00.01


FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*  
PROJECTED ITERATIONS: 7 TO 298  
PROJECTED ANSWERS: 4 TO 200

L2 4 SEA SSS SAM L1

=> d scan

L2 4 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN  
IN Acetic acid, [1-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-3-pyrrolidinylidene]cyano-, ethyl ester (9CI)  
MF C21 H23 F N4 O5  
CI COM

Absolute stereochemistry.  
Double bond geometry unknown.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> s l1 ful

FULL SEARCH INITIATED 18:24:25 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 159 TO ITERATE

100.0% PROCESSED 159 ITERATIONS 61 ANSWERS  
SEARCH TIME: 00.00.01

L3 61 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION

10/694,843

FULL ESTIMATED COST

155.84

156.05

FILE 'CAPLUS' ENTERED AT 18:24:31 ON 09 DEC 2004  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 9 Dec 2004 VOL 141 ISS 24  
FILE LAST UPDATED: 8 Dec 2004 (20041208/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l3

L4 4 L3

=> d l4 ibib hitstr abs 1-4

L4 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2004:372882 CAPLUS

DOCUMENT NUMBER: 140:391269

TITLE: Preparation of methyldiene oxazolidinone compounds as antimicrobial agents and preparation method thereof

INVENTOR(S): Koh, Hun Yeong; Cho, Yong Seo; Pae, Ae Nim; Cha, Joo Hwan; Kim, Hye Yeon; Lee, Jae Seok; Kim, Hak Soo; Kim, Sanghee

PATENT ASSIGNEE(S): Korea Institute of Science and Technology, S. Korea

SOURCE: U.S. Pat. Appl. Publ., 14 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004087633	A1	20040506	US 2003-694843	20031029
PRIORITY APPLN. INFO.:			KR 2002-66268	A 20021029

OTHER SOURCE(S): CASREACT 140:391269; MARPAT 140:391269

IT 685570-69-8P, N-[[[(5S)-3-[3-Fluoro-4-[4-(1-cyano-4-hydroxybutylidene)piperidin-1-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)


(preparation of 3-[4-(3-methyldienepiperidin-1-yl or 4-methyldienepyrrolidin-1-yl)phenyl]-2-oxazolidinone derivs. as antimicrobial agents)

10/694,843

RN 685570-69-8 CAPLUS

CN Acetamide, N-[[[(5S)-3-[4-[4-(1-cyano-4-hydroxybutylidene)-1-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 596136-10-6P, N-[[[(5S)-3-[3-Fluoro-4-[3-(dicyanomethylidene)pyrrolidin-1-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide 596136-11-7P 596136-13-9P  
648919-57-7P, N-[[[(5S)-3-[3-Fluoro-4-[4-(1-cyanoethylidene)piperidin-1-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide 648919-89-5P, N-[[[(5S)-3-[3-Fluoro-4-[4-(dicyanomethylidene)piperidin-1-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide 648919-97-5P, N-[[[(5S)-3-[3-Fluoro-4-[4-(1-ethoxycarbonyl-1-cyanomethylidene)piperidin-1-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide 685570-68-7P, N-[[[(5S)-3-[3-Fluoro-4-[4-[1-cyano-2-(ethoxycarbonyl)ethylidene]piperidin-1-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide 685570-70-1P, N-[[[(5S)-3-[3-Fluoro-4-[4-[1-cyano-4-(methanesulfonyloxy)butylidene]piperidin-1-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide 685570-73-4P,  
N-[[[(5S)-3-[3-Fluoro-4-[4-(1-cyano-4-aminobutylidene)piperidin-1-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]thioacetamide 685570-79-0P  
, N-[[[(5S)-3-[3-Fluoro-4-[4-[1-(ethoxycarbonyl)ethylidene]piperidin-1-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide 685570-82-5P,  
N-[[[(5S)-3-[3-Fluoro-4-[4-[1-chloro-1-(ethoxycarbonyl)methylidene]piperidin-1-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide 685570-96-1P  
, N-[[[(5S)-3-[3-Fluoro-4-[3-(dicyanomethylidene)pyrrolidin-1-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide hydrochloride 685570-97-2P  
685570-99-4P 685571-00-0P, N-[[[(5S)-3-[3-Fluoro-4-[4-[1-cyano-2-(ethoxycarbonyl)ethylidene]piperidin-1-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide hydrochloride 685571-01-1P,  
N-[[[(5S)-3-[3-Fluoro-4-[4-(1-ethoxycarbonyl-1-cyanomethylidene)piperidin-1-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide hydrochloride  
685571-07-7P, N-[[[(5S)-3-[3-Fluoro-4-[4-[1-(ethoxycarbonyl)ethylidene]piperidin-1-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide hydrochloride 685571-09-9P,  
N-[[[(5S)-3-[3-Fluoro-4-[4-[1-chloro-1-(ethoxycarbonyl)methylidene]piperidin-1-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide hydrochloride

10/694,843

**685571-10-2P**, N-[[[(5S)-3-[3-Fluoro-4-[4-(1-cyanoethylidene)piperidin-1-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide hydrochloride


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 3-[4-(3-methylidenepiperidin-1-yl or 4-methylidenepyrrolidin-1-yl)phenyl]-2-oxazolidinone derivs. as antimicrobial agents)

RN 596136-10-6 CAPLUS

CN Acetamide, N-[[[(5S)-3-[4-[3-(dicyanomethylene)-1-pyrrolidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 596136-11-7 CAPLUS

CN Acetic acid, [1-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-3-pyrrolidinylidene]cyano-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 596136-13-9 CAPLUS

CN Acetamide, N-[[[(5S)-3-[4-[3-(1-cyanoethylidene)-1-pyrrolidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.


10/694,843



RN 648919-57-7 CAPLUS

CN Acetamide, N-[[[(5S)-3-[4-[4-(1-cyanoethylidene)-1-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 648919-89-5 CAPLUS

CN Acetamide, N-[[[(5S)-3-[4-[4-(dicyanomethylene)-1-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

10/694,843



RN 648919-97-5 CAPLUS  
CN Acetic acid, [1-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-4-piperidinylidene]cyano-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 685570-68-7 CAPLUS  
CN Propanoic acid, 3-[1-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-4-piperidinylidene]-3-cyano-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/694,843



RN 685570-70-1 CAPLUS

CN Acetamide, N-[[[(5S)-3-[4-[4-[1-cyano-4-[(methanesulfonyl)oxy]butylidene]-1-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 685570-73-4 CAPLUS

CN Ethanethioamide, N-[[[(5S)-3-[4-[4-(4-amino-1-cyanobutylidene)-1-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

NC(=S)CNC1CCOC(=O)N1c2ccc(F)cc2N3CCCCC3C(=N)C(C)N


Absolute stereochemistry.



Page 10.

10/694,843


Absolute stereochemistry.



RN 685570-96-1 CAPLUS

CN Acetamide, N-[[[(5S)-3-[4-[3-(dicyanomethylene)-1-pyrrolidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl


RN 685570-97-2 CAPLUS

CN Acetic acid, [1-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-3-pyrrolidinylidene]cyano-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.

10/694,843




● HCl

RN 685570-99-4 CAPLUS

CN Acetamide, N-[[[(5S)-3-[4-[3-(1-cyanoethylidene)-1-pyrrolidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




● HCl

RN 685571-00-0 CAPLUS

CN Propanoic acid, 3-[1-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-4-piperidinylidene]-3-cyano-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/694,843



RN 685571-01-1 CAPLUS

CN Acetic acid, [1-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-4-piperidinylidene]cyano-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 685571-07-7 CAPLUS

CN Propanoic acid, 2-[1-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-4-piperidinylidene]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/694,843



RN 685571-09-9 CAPLUS

CN Acetic acid, [1-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-4-piperidinylidene]chloro-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 685571-10-2 CAPLUS

CN Acetamide, N-[[[(5S)-3-[4-[4-(1-cyanoethylidene)-1-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)

10/694,843

Absolute stereochemistry.



IT 685570-71-2P, N-[[[(5S)-3-[3-Fluoro-4-[4-(1-cyano-4-azidobutylidene)piperidin-1-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide


RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(reactant; preparation of 3-[4-(3-methylidenepiperidin-1-yl or 4-methylidenepyrrolidin-1-yl)phenyl]-2-oxazolidinone derivs. as antimicrobial agents)

RN 685570-71-2 CAPLUS

CN Acetamide, N-[[[(5S)-3-[4-[4-(4-azido-1-cyanobutylidene)-1-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/694,843



IT 685570-72-3


RL: RCT (Reactant); RACT (Reactant or reagent)  
(reactant; preparation of 3-[4-(3-methylidenepiperidin-1-yl or  
4-methylidenepyrrolidin-1-yl)phenyl]-2-oxazolidinone derivs. as  
antimicrobial agents)

RN 685570-72-3 CAPLUS


CN Acetamide, N-[[[(5S)-3-[4-[4-[1-cyano-2-[(methylsulfonyl)oxy]butylidene]-1-  
piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA  
INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 2-A



GI



AB 3-[4-(3-Methylidenepiperidin-1-yl or 4-methylidenepyrrolidin-1-yl)phenyl]-2-oxazolidinone compds. represented by formula (I) or pharmaceutically acceptable salt thereof (R1 and R2 independently represent H, cyano, alkyl, halogen, acetoxy, ethoxycarbonyl, hydroxy, hydroxyimino, methoxyimino, aminoethyl, or a unsatd. 5-membered heterocyclic substituent containing one or more hetero atoms selected from the group consisting of O, N and S; n represents an integer 1 or 2), showing superior antimicrobial

activities against gram-pos. germs including resistant strains such as methicillin-resistant staphylococcus aureus and vancomycin-resistant enterococcus, are prepared Also disclosed is a preparation method thereof. These compds. showing superior antimicrobial activities against gram-pos. germs including resistant strains such as methicillin-resistant staphylococcus aureus and vancomycin-resistant enterococcus. For example, N-[[[(5S)-3-[3-fluoro-4-[4-(cyanomethylidene)piperidin-1-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]thioacetamide showed min. inhibitory concentration of 0.5 µg/mL against vancomycin-resistant Staphylococcus pyogenes C6487 vs. 2 and >32 µg/mL for linezolid and vancomycin, resp.

L4 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2004:60503 CAPLUS

DOCUMENT NUMBER: 140:128407

TITLE: Preparation of (piperidinophenyl)oxazolidinones targeting multiple ribonucleoprotein sites as antibacterial agents

INVENTOR(S): Patel, Mahesh V.; Deshpande, Prasad K.; Sindkhedkar, Milind D.; Gupte, Shrikant V.; Chugh, Yati; Shetty, Nitin; Shukla, Milind C.; Yeole, Ravindra D.; De Souza, Noel J.

PATENT ASSIGNEE(S): India

SOURCE: PCT Int. Appl., 156 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004007489	A2	20040122	WO 2003-IN238	20030710
WO 2004007489	A3	20040318		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: US 2002-395164P P 20020711

OTHER SOURCE(S): MARPAT 140:128407

IT 648919-57-7P 648919-72-6P 648919-80-6P

648919-83-9P 648919-85-1P 648919-88-4P

648919-89-5P 648919-90-8P 648919-93-1P

648919-94-2P 648919-95-3P 648919-97-5P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)


(preparation of cyanomethylenepiperidinophenyl oxazolidinones targeting multiple RNA sites as antibacterial agents)

RN 648919-57-7 CAPLUS

CN Acetamide, N-[[[(5S)-3-[4-[4-(1-cyanoethylidene)-1-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/694,843



RN 648919-72-6 CAPLUS

CN Acetamide, N-[[[(5S)-3-[4-[4-(1-cyanopropylidene)-1-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 648919-80-6 CAPLUS

CN Acetamide, N-[[[(5S)-3-[4-[4-(1-cyano-2-phenylethylidene)-1-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/694,843



RN 648919-83-9 CAPLUS

CN Acetamide, N-[[[(5S)-3-[4-[4-(cyano-2-pyridinylmethylene)-1-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 648919-85-1 CAPLUS

CN Acetamide, N-[[[(5S)-3-[4-[4-(cyano-1H-imidazol-1-ylmethylene)-1-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/694,843



RN 648919-88-4 CAPLUS

CN Acetamide, N-[[[(5S)-3-[4-[4-(cyano-2-thienylmethylene)-1-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 648919-89-5 CAPLUS

CN Acetamide, N-[[[(5S)-3-[4-[4-(dicyanomethylene)-1-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/694,843



RN 648919-90-8 CAPLUS

CN Acetamide, 2-[1-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-4-piperidinylidene]-2-cyano- (9CI) (CA INDEX NAME)



Absolute stereochemistry.



RN 648919-93-1 CAPLUS


CN Acetamide, 2-[1-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-4-piperidinylidene]-2-cyano-N-cyclohexyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 648919-94-2 CAPLUS  
 CN Acetamide, N-[[[(5S)-3-[4-[4-[1-cyano-2-oxo-2-(1-pyrrolidinyl)ethylidene]-1-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA  
 INDEX NAME)

Absolute stereochemistry.




10/694,843

RN 648919-95-3 CAPLUS

CN Acetamide, N-[[[(5S)-3-[4-[4-[1-cyano-2-(4-morpholinyl)-2-oxoethylidene]-1-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl)methyl]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 648919-97-5 CAPLUS

CN Acetic acid, [1-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-4-piperidinylidene]cyano-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 648919-58-8P 648919-59-9P 648919-60-2P  
 648919-61-3P 648919-62-4P 648919-63-5P  
 648919-67-9P 648919-68-0P 648919-69-1P  
 648919-70-4P 648919-73-7P 648919-74-8P  
 648919-75-9P 648919-76-0P 648919-78-2P  
 648919-79-3P 648919-84-0P 648919-86-2P  
 648919-87-3P 648919-91-9P 648919-92-0P  
 648919-96-4P 648920-00-7P 648920-01-8P  
 648920-02-9P 648920-03-0P 648920-04-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)


(preparation of cyanomethylenepiperidinophenyl oxazolidinones targeting  
 multiple RNA sites as antibacterial agents)

RN 648919-58-8 CAPLUS

CN Acetamide, 2-cyano-N-[[[(5S)-3-[4-[4-(1-cyanoethylidene)-1-piperidinyl]-3-  
 fluorophenyl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/694,843



RN 648919-59-9 CAPLUS

CN Acetamide, 2-amino-N-[[[(5S)-3-[4-[4-(1-cyanoethylidene)-1-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 648919-60-2 CAPLUS

CN Acetamide, N-[[[(5S)-3-[4-[4-(1-cyanoethylidene)-1-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]-2,2-difluoro- (9CI) (CA INDEX NAME)

10/694,843


Absolute stereochemistry.



RN 648919-61-3 CAPLUS

CN Acetamide, 2-chloro-N-[[[(5S)-3-[4-[4-(1-cyanoethylidene)-1-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 648919-62-4 CAPLUS

CN Acetamide, 2,2-dichloro-N-[[[(5S)-3-[4-[4-(1-cyanoethylidene)-1-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

10/694,843


Absolute stereochemistry.



RN 648919-63-5 CAPLUS

CN Acetamide, 2,2,2-trichloro-N-[[[(5S)-3-[4-[4-(1-cyanoethylidene)-1-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 648919-67-9 CAPLUS

CN Ethanethioamide, N-[[[(5S)-3-[4-[4-(1-cyanoethylidene)-1-piperidinyl]-3-

10/694,843

fluorophenyl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 648919-68-0 CAPLUS

CN Acetamide, N-[[[(5S)-3-[4-[4-(1-cyanoethylidene)-3-fluoro-1-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 648919-69-1 CAPLUS

CN Acetamide, N-[[[(5S)-3-[4-[(4E)-4-(1-cyanoethylidene)-3-fluoro-1-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA

10/694,843

INDEX NAME)


Absolute stereochemistry.  
Double bond geometry as shown.



RN 648919-70-4 CAPLUS

CN Acetamide, N-[[[(5S)-3-[4-[(4Z)-4-(1-cyanoethylidene)-3-fluoro-1-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.




RN 648919-73-7 CAPLUS

CN Acetamide, 2,2-dichloro-N-[[[(5S)-3-[4-[4-(1-cyanopropylidene)-1-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

10/694,843

INDEX NAME)


Absolute stereochemistry.



RN 648919-74-8 CAPLUS

CN Acetamide, 2,2,2-trichloro-N-[[[(5S)-3-[4-[4-(1-cyanopropylidene)-1-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA  
INDEX NAME)

Absolute stereochemistry.




RN 648919-75-9 CAPLUS

10/694,843

CN Acetamide, 2-bromo-N-[[[(5S)-3-[4-[4-(1-cyanopropylidene)-1-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 648919-76-0 CAPLUS

CN Ethanethioamide, N-[[[(5S)-3-[4-[4-(1-cyanopropylidene)-1-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 648919-78-2 CAPLUS

10/694,843

CN Acetamide, N-[[ (5S)-3-[4-[4-(1-cyano-3-butenylidene)-1-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 648919-79-3 CAPLUS

CN Acetamide, N-[[ (5S)-3-[4-[4-(1-cyano-3-butynylidene)-1-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 648919-84-0 CAPLUS

CN Acetamide, N-[[ (5S)-3-[4-[4-[1-cyano-2-(4-morpholinyl)ethylidene]-1-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

10/694,843


Absolute stereochemistry.



RN 648919-86-2 CAPLUS

CN Acetamide, N-[[[(5S)-3-[4-[4-[cyano(2-methyl-1H-imidazol-1-yl)methylene]-1-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 648919-87-3 CAPLUS

CN Acetamide, N-[[[(5S)-3-[4-[4-(cyano-1H-1,2,4-triazol-1-ylmethylene)-1-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/694,843



RN 648919-91-9 CAPLUS

CN Acetamide, 2-[1-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-4-piperidinylidene]-2-cyano-N-2-propenyl- (9CI) (CA INDEX NAME)



Absolute stereochemistry.



RN 648919-92-0 CAPLUS

CN Acetamide, 2-[1-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-4-piperidinylidene]-2-cyano-N-cyclopropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 648919-96-4 CAPLUS  
 CN Acetamide, N-[[[(5S)-3-[4-[4-(1-cyano-3-hydroxypropylidene)-1-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl)methyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/694,843



RN 648920-00-7 CAPLUS

CN Acetamide, N-[[[(5S)-3-[4-[4-(bromocyanomethylene)-1-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)



Absolute stereochemistry.



RN 648920-01-8 CAPLUS

CN Ethanethioamide, N-[[[(5S)-3-[4-[4-(cyano-2-pyridinylmethylene)-1-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 648920-02-9 CAPLUS  
 CN Ethanethioamide, N-[[[(5S)-3-[4-[4-(dicyanomethylene)-1-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/694,843




RN 648920-03-0 CAPLUS

CN Acetamide, 2-cyano-2-[1-[2-fluoro-4-[(5S)-2-oxo-5-[[1-(thiooxoethyl)amino]methyl]-3-oxazolidinyl]phenyl]-4-piperidinylidene]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



10/694,843


PAGE 2-A

||  
S

RN 648920-04-1 CAPLUS  
CN Ethanethioamide, N-[[[(5S)-3-[4-[4-[1-cyano-2-(4-morpholinyl)-2-thioxoethylidene]-1-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 2-A

||  
S

GI



AB Title compds. I [wherein R1 = H, (un)substituted (cyclo)alkyl, (un)substituted alkanoyl, arylmercapto, heterocyclylthiocarbonyl, etc.; R2, R3 = H, halogen; R4 = alkylsulfonyloxy, (un)substituted alkylthiocarbonylamino, (un)substituted ureido, carbamato, etc.; A, B = independently selected from H, alkyl, CO2Et, halogen; and salts or solvates thereof] were prepared as antibacterial agents. For example, reaction of (S)-N-[3-[4-(4-cyanomethylidenepiperidin-1-yl)-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]amine with carbon disulfide (69%), followed by addition of sodium methoxide, gave II in 77% yield. II showed 1.56-6.25 µg/mL (MIC) against linezolid resistant strains, such as *S. aureus* MRSA-32, *S. pneumoniae* SPN744 and *E. faecium* 367, 0.2 µg/mL (MIC) against linezolid sensitive strains, such as *S. aureus* MRSA-32 and *S. pneumoniae* 49619, 1.56 (MPC) for the treatment of *E. faecalis* 416 infection, and etc. 3D quant. structure activity relationship (3D-QSAR) showed that the steric contributions of I are over one and half times more than the electrostatic contributions, compared to literature compds. Thus, I and their pharmaceutical compds. targeting multiple ribonucleoprotein sites are useful as antimicrobial agents for treating bacterial infections.

L4 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2004:60502 CAPLUS

DOCUMENT NUMBER: 140:128406

TITLE: Preparation of (piperidinophenyl)oxazolidinones as antimicrobial agents with improved pharmacokinetic profile and safety advantages

INVENTOR(S): Chugh, Yati; Shetty, Nitin; Deshpande, Prasad K.; Sindkhedkar, Milind D.; Jafri, Mohammad A.; Yeole, Ravindra D.; Shukla, Milind C.; Gupte, Shrikant V.; Patel, Mahesh V.; De Souza, Noel J.

PATENT ASSIGNEE(S): India

SOURCE: PCT Int. Appl., 44 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004007488	A2	20040122	WO 2003-IN237	20030710
WO 2004007488	A3	20040318		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,

10/694,843

CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,  
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,  
PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN,  
TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW  
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,  
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,  
FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,  
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2004063954 A1 20040401 US 2003-616888 20030710

US 2004235900 A1 20041125 US 2003-475735 20031023

PRIORITY APPLN. INFO.:

US 2002-395164P P 20020711

IN 2003-MU392 A 20030421

WO 2003-IN237 W 20030710

OTHER SOURCE(S): CASREACT 140:128406; MARPAT 140:128406

IT 648919-57-7 648919-72-6 648919-89-5

653597-37-6 653597-38-7 653597-47-8


RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of (cyanoalkylpiperidinophenyl)oxazolidinones as antimicrobial agents with improved pharmacokinetic profile and safety advantages)

RN 648919-57-7 CAPLUS

CN Acetamide, N-[[[(5S)-3-[4-[4-(1-cyanoethylidene)-1-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 648919-72-6 CAPLUS

CN Acetamide, N-[[[(5S)-3-[4-[4-(1-cyanopropylidene)-1-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

10/694,843



RN 648919-89-5 CAPLUS  
CN Acetamide, N-[[[(5S)-3-[4-[4-(dicyanomethylene)-1-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 653597-37-6 CAPLUS  
CN Acetamide, N-[[[(5S)-3-[4-[4-(1-cyanobutylidene)-1-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/694,843



RN 653597-38-7 CAPLUS

CN Acetamide, N-[[[(5S)-3-[4-[4-(1-cyano-2-hydroxyethylidene)-1-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 653597-47-8 CAPLUS

CN Acetic acid, [1-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-4-piperidinylidene]cyano-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



GI



I




II

AB Title compds. I•A [wherein R1 = H, (un)substituted alkyl, CO<sub>2</sub>H, CN; R2, R3 = H, F; R4 = (un)substituted alkyl, alkoxy; D = H, alkyl, F; A = absent or a complex forming agent, organic base, amino acid] were prepared as antimicrobial agents. For example, reduction of N-[[[(S)-3-[4-(4-cyanomethylidenepiperidin-1-yl)-3-fluorophenyl]-2-oxooxazolidin-5-yl]methyl]acetamide with 10% Pd/C afforded II in 89% yield. II showed 1.0-2.0 µg/mL (MIC) against *S. aureus* MRSA-32, *E. faecalis* ATCC 29212 and *S. pneumoniae* ATCC 49619, good pharmacokinetic values, such as a higher 12-h blood level and a longer half-life than the control, and no toxicity. Thus, I and their pharmaceutical compds. have an improved pharmacokinetic profile and no toxicity in use as antimicrobial agents for preventing and treating bacterial infections in once-a-day doses.

10/694,843


DOCUMENT NUMBER: 139:245931  
TITLE: Synthesis and in vitro activity of new methylenepiperidinyl and methylenepyrrolidinyl oxazolidinone antibacterial agents  
AUTHOR(S): Kim, Hye Yeon; Lee, Jae Seok; Cha, Joo Hwan; Pae, Ae Nim; Cho, Yong Seo; Chang, Moon Ho; Koh, Hun Yeong  
CORPORATE SOURCE: Biochemicals Research Center, Korea Institute of Science and Technology, Cheongryang, Seoul, 130-650, S. Korea  
SOURCE: Bioorganic & Medicinal Chemistry Letters (2003), 13(13), 2227-2230  
CODEN: BMCLE8; ISSN: 0960-894X  
PUBLISHER: Elsevier Science B.V.  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
OTHER SOURCE(S): CASREACT 139:245931  
IT 596136-10-6P 596136-11-7P 596136-13-9P  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
(synthesis and in vitro activity of [(methylenepiperidinyl) or (methylenepyrrolidinyl)fluorophenyl]oxazolidinone antibacterial agents)  
RN 596136-10-6 CAPLUS  
CN Acetamide, N-[[[(5S)-3-[4-[3-(dicyanomethylene)-1-pyrrolidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 596136-11-7. CAPLUS  
CN Acetic acid, [1-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-3-pyrrolidinylidene]cyano-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry unknown.




RN 596136-13-9 CAPLUS  
CN Acetamide, N-[[[(5S)-3-[4-[3-(1-cyanoethylidene)-1-pyrrolidinyl]-3-


10/694,843

fluorophenyl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry unknown.



GI



I

AB A series of substituted methylenepiperidiny and methylenepyrrolidinyl oxazolidinones I (R1 = H, Me, CN; R2 = CN, CO2Et, COMe, CHO, etc.) have been prepared and evaluated for antibacterial activity against several gram-pos. strains, including the resistant strains of Staphylococcus and Enterococcus, such as MRSA, CRSA, MSSA and VRE. Some of them showed comparable or superior in vitro activities (MIC) to vancomycin.

REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> log y

COST IN U.S. DOLLARS

SINCE FILE TOTAL

ENTRY SESSION

FULL ESTIMATED COST

19.92 175.97

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE TOTAL

ENTRY SESSION

CA SUBSCRIBER PRICE

-2.80 -2.80

STN INTERNATIONAL LOGOFF AT 18:25:37 ON 09 DEC 2004